PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate Cancer Clinical Trial

— OCEAN  

Official title:

A Phase II Trial of PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - The OCEAN Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06392295
• Other study ID #: 20231278
• Status: Recruiting
• Phase: Phase 2
• Start date: August 1, 2024
• Est. completion date: August 1, 2029

Study information

• Verified date: May 2024
• Source: University of Miami
• Contact: Benjamin J Rich, MD
• Phone: 305-243-4200
• Email: brich[@]miami.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this prostate cancer research study is to learn about:

1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy;

2. Preserving quality of life after radiation therapy;

3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: August 1, 2029
• Est. primary completion date: August 1, 2027
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically proven prostate adenocarcinoma

2. Male, = 18 years old

3. Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes

• a. No more than a total of 5 lesions on PSMA PET/CT scan (each lesion defined as positive with standardized uptake value (SUV) > liver uptake and CT scan correlate)

• b. No disease outside of the pelvic and sub-diaphragmatic para-aortic lymph nodes

• c. At least one lesion in the sub-diaphragmatic para-aortic lymph nodes

• d. Non-bulky nodal disease (ie, tumor <5 cm)

4. Prior pelvic radiation with disease response

• a. Definitive radiation therapy to the prostate with or without treatment of the pelvic lymph nodes and/or

• b. Salvage or adjuvant radiation therapy to the prostate bed following prostatectomy with or without treatment of the pelvic lymph nodes

5. Hormone-sensitive prostate cancer

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

7. Ability to understand the investigational nature, potential risks and benefits of the research study, and willingness to sign the written informed consent and HIPAA document(s)

8. Willingness to fill out quality of life and psychosocial forms

9. Willingness to participate in our institution's Prostate Cancer Database Protocol (ID# 20090767)

Exclusion Criteria:

1. No pathological diagnosis of prostate adenocarcinoma

2. Patient has more than 5 sites of metastatic disease

3. Patient has history of bone and/or visceral metastasis

4. No evidence of disease in the para-aortic lymph nodes

5. No staging with PSMA PET/CT scan

6. History of prior radiation therapy outside the pelvis for prostate cancer

7. Bulky nodal disease >5 cm in tumor size

8. Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET/CT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment

9. Suspicious radiologic evidence of disease in the prostate on staging PSMA PET/CT scan without confirmatory negative prostate biopsy

10. Implanted hardware which limits treatment planning or delivery (determined by treating physician)

11. Castration-resistant prostate cancer (history of rising PSA with serum testosterone level <50 ng/dL)

12. Patients with ECOG performance status > 2

13. History of inflammatory bowel disease

14. History of malignancy other than prostate cancer except for non-melanoma skin cancer

15. Patients unable to consent or are prisoners

16. Unwilling to fill out quality of life and psychosocial forms

17. Participants with impaired decision-making capacity

Related Conditions & MeSH terms

• Hormone Sensitive Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Radiation:
• Para Aortic Radiation Therapy: Photon Therapy
Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 50 grays (Gys) delivered in 25 fractions to the Clinical Tumor Volume (CTV).
• Para Aortic Radiation Therapy: Proton Therapy
Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 60 to 65 Gys delivered in 25 fractions to the Gross Tumor Volume (GTVn).

Drug:
• Androgen Deprivation Therapy
Androgen deprivation therapy will be administered as per standard of care.
• Androgen Receptor Signaling Inhibitor
Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS)	Progression-free survival (PFS) among participants will be assessed during treatment and clinical follow-up. PFS is defined as the time from start of treatment until any of the following: Biochemical failure, escalation of therapy, radiological evidence of disease progression or death of any cause. Radiological evidence of disease progression will be assessed by the treating physician using the Response Evaluation Criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) version 1.0.	Up to 2 years
Secondary	Biochemical Failure-Free Survival (FFS)	Biochemical failure-free survival among participants will be assessed during treatment and clinical follow-up. Biochemical failure-free survival is defined as the time from study enrollment to time of biochemical failure. Biochemical failure, as adapted from the Prostate Cancer Working Group 2 (PCWG2), is defined as when prostate-specific antigen (PSA) level increases = 25% and = 2 ng/mL above the nadir, which is confirmed by a second value obtained three or more weeks later.	Up to 2 years
Secondary	Metastasis-Free Survival	Metastasis-free survival among participants will be assessed during treatment and clinical follow-up. Metastasis-free survival is defined as the time from study enrollment to clinical or radiological evidence of metastatic disease or death.	Up to 2 years
Secondary	Overall Survival (OS)	Overall survival (OS) among participants will be assessed. OS is defined as the time from study enrollment to death of any cause.	Up to 2 years
Secondary	Median Cause Specific Survival	Median case specific survival among participants will be assessed. Median cause specific survival is defined as the time from study enrollment to death secondary to prostate cancer.	Up to 2 years
Secondary	Proportion of Participants Undergoing Escalation of Therapy	The proportion of participants undergoing escalation of therapy will be reported. Escalation of therapy is defined as subsequent course of radiation therapy or change in systemic therapy (except for intolerable side effects).	Up to 2 years
Secondary	Proportion of Participants Experiencing Cumulative Late Grade = 2 Treatment-Related Toxicity	The proportion of participants experience late grade = 2 treatment related toxicity between 90 days and two years following para-aortic radiation therapy (PA-RT) will be reported. Late toxicity is defined as Grade = 2 treatment-related toxicities occurring more than 90 days after completing para-aortic radiation therapy (PA-RT). The severity of the reactions to the treatment will be assessed according to using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Up to 2 years
Secondary	Change in Quality of Life Scores: EPIC 26 Short Form	Health-related Quality of Life (HRQOL) will be measured using the Expanded Prostate Cancer Index Composite 26 Short Form (EPIC-26) to evaluate patient function and satisfaction after prostate cancer treatment. EPIC-26 is a short form version of the Expanded Prostate Cancer Index Composite, and is a validated comprehensive instrument developed to measure the health-related quality of life among men with prostate cancer. EPIC-26 consists of 26 items under 5 domains of urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal. Response options for each item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.	Up to 2 years
Secondary	Change in Quality of Life Scores: HADS	Health-related Quality of Life (HRQOL) will be measured using the Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a validated instrument used to measure patient symptoms of anxiety and depression. The HADS questionnaire consists of six questions, three questions each in two domains, HADS-Anxiety and HADS-Depression. Scores in each domain range from 0-9, with higher scores representing greater levels of anxiety and depression.	Up to 2 years
Secondary	Change in Quality of Life Scores: IPSS	Health-related quality of life (HRQOL) will be measured using the International Prostate Symptom Score (IPSS) to evaluate patient urinary function and quality of life. There are 7 questions related to urinary function. Responses are on a scale from 0 ("not at all") to 5 ("almost always"), with higher scores indicating higher levels of urinary dysfunction. There is one quality of life question related to urinary symptoms. Responses are on a scale from 0 ("delighted") to 6 ("terrible"). Responses will be tabulated for a composite score.	Up to 2 years
Secondary	Complete Early Response Rate	The Complete Early Response rate among participants will be reported. Complete Early Response is defined as seen as on the 3-month post-PA-RT PSMA PET/CT scan using the Response Evaluation Criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) version 1.0; or a PSA level = 0.1 ng/mL. A composite of these two evaluations will be used to determine the complete early response rate.	Up to 2 years